American Renal Associates Holdings, Inc (NYSE:ARA) – Equities researchers at SunTrust Banks decreased their FY2017 earnings estimates for American Renal Associates Holdings in a research report issued to clients and investors on Wednesday. SunTrust Banks analyst D. Macdonald now expects that the company will post earnings per share of $0.57 for the year, down from their previous estimate of $0.58. SunTrust Banks currently has a “Buy” rating and a $18.00 target price on the stock. SunTrust Banks also issued estimates for American Renal Associates Holdings’ Q4 2017 earnings at $0.16 EPS, Q2 2018 earnings at $0.19 EPS, Q3 2018 earnings at $0.20 EPS, Q4 2018 earnings at $0.23 EPS, FY2018 earnings at $0.73 EPS, Q1 2019 earnings at $0.16 EPS, Q2 2019 earnings at $0.22 EPS, Q3 2019 earnings at $0.24 EPS and FY2019 earnings at $0.86 EPS.
American Renal Associates Holdings (NYSE:ARA) last issued its quarterly earnings results on Tuesday, November 14th. The company reported $0.19 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.16 by $0.03. The company had revenue of $187.71 million for the quarter, compared to the consensus estimate of $194.60 million. American Renal Associates Holdings had a negative net margin of 2.15% and a positive return on equity of 15.80%. The firm’s quarterly revenue was down 2.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.28 EPS. TRADEMARK VIOLATION NOTICE: This report was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://sportsperspectives.com/2017/11/19/fy2017-eps-estimates-for-american-renal-associates-holdings-inc-decreased-by-analyst-ara.html.
American Renal Associates Holdings (NYSE:ARA) opened at $13.03 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.16 and a debt-to-equity ratio of 3.57. The firm has a market cap of $409.94, a PE ratio of 19.45, a P/E/G ratio of 1.13 and a beta of 3.64. American Renal Associates Holdings has a fifty-two week low of $9.91 and a fifty-two week high of $24.94.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Citigroup Inc. lifted its holdings in American Renal Associates Holdings by 1,876.9% during the second quarter. Citigroup Inc. now owns 8,046 shares of the company’s stock valued at $149,000 after purchasing an additional 7,639 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in American Renal Associates Holdings by 19.7% during the second quarter. The Manufacturers Life Insurance Company now owns 8,778 shares of the company’s stock valued at $162,000 after purchasing an additional 1,443 shares during the last quarter. Citadel Advisors LLC purchased a new stake in American Renal Associates Holdings during the third quarter valued at about $200,000. Atria Investments LLC lifted its holdings in American Renal Associates Holdings by 2.2% during the second quarter. Atria Investments LLC now owns 10,943 shares of the company’s stock valued at $203,000 after purchasing an additional 233 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new stake in American Renal Associates Holdings during the second quarter valued at about $230,000. 89.98% of the stock is currently owned by institutional investors and hedge funds.
American Renal Associates Holdings Company Profile
American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.
Receive News & Ratings for American Renal Associates Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.